CDEK
← All drugs Report issue

carbinoxamine maleate

Trade name: clistin

Small moleculeapproved

Approved

Jun 1, 1958

Carbinoxamine is a histamine-H1 receptor blocking agent. It is an antihistamine with anticholinergic (drying) and sedative properties. Carbinoxamine appears to compete with histamine (type H1) for receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract. Carbinoxamine is effective for the symptomatic treatment of seasonal and perennial allergic rhinitis; vasomotor rhinitis; allergic conjunctivitis due to inhalant allergens and foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Most common adverse reactions are: sedation, sleepiness, dizziness, disturbed coordination, epigastric distress, and thickening of bronchial secretions. Avoid concomitant use of alcohol and CNS depressants (hypnotics sedatives, tranquilizers, etc.) due to additive adverse effects. — NCATS

Clinical trial activity

2 trials · 2 clinical orgs · 14 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
1

Earliest trial started May 1, 2017 (NCT02981147)

Timeline

1950s

  1. Jun 1, 1958

    Earliest FDA Approval

1970s

  1. Dec 27, 1974

    McNeil — First NDA Organization

  2. Dec 27, 1974

    McNeil — NDA Organization

  3. Dec 27, 1974

    Johnson and Johnson — NDA Secondary Org

2000s

  1. Mar 19, 2003

    Mikart — Marketing Organization

  2. Mar 19, 2003

    Genus Oncology, LLC — Marketing Organization

  3. Feb 26, 2008

    Vintage — Marketing Organization

  4. Feb 26, 2008

    Apax Partners — Marketing Organization

  5. Feb 26, 2008

    Endo Pharmaceuticals — Marketing Organization

  6. May 30, 2008

    Strides Pharma Science — Marketing Organization

2010s

  1. Apr 15, 2010

    Invagen Pharms — Marketing Organization

  2. May 4, 2010

    Cypress Pharmaceutical — Marketing Organization

  3. May 27, 2011

    Mission Pharmacal — Marketing Organization

  4. Mar 28, 2013

    AYTU BioScience — Marketing Organization

  5. Mar 28, 2013

    Tris Pharma, Inc. — NDA Secondary Org

  6. Mar 28, 2013

    AYTU BioScience — NDA Secondary Org

  7. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Dec 19, 2024

    Leading Pharma Llc — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedJun 1, 1958

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CCOC(c1ccc(Cl)cc1)c1ccccn1
Mol. weight
290.79 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • {2-[(4-chloro-phenyl)-pyridin-2-yl-methoxy]-ethyl}-dimethyl-amine
  • {2-[(4-chloro-phenyl)-pyridin-2-yl-methoxy]-ethyl}-dimethyl-amine
  • 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine
  • 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine
  • carbinoxamin
  • carbinoxamin
  • carbinoxamina
  • carbinoxamina
  • carbinoxamine
  • carbinoxamine
  • carbinoxamine
  • carbinoxamine
  • carbinoxamine
  • carbinoxamine
  • carbinoxamine
  • carbinoxamine
  • (+-)-carbinoxamine
  • (+-)-carbinoxamine
  • carbinoxamine base
  • carbinoxamine base
  • carbinoxamine diphenyldisulfonate
  • carbinoxamine maleate
  • carbinoxamine maleate
  • carbinoxamine maleate
  • carbinoxamine maleate
  • carbinoxamine maleate
  • carbinoxamine maleate
  • carbinoxamine tannate
  • carbinoxamine tannate
  • carbinoxamine tannate
  • carbinoxamine tannate
  • carbinoxamine tannate
  • carbinoxaminum
  • carbinoxaminum
  • cisti
  • clistin
  • clistin
  • clistin
  • davenol
  • histex ct
  • histex i-e
  • histex pd
  • n,n-dimethyl-2-(p-chloro-alpha-(2-pyridyl)benzyloxy)ethylamine
  • palgic
  • palgic
  • paracarbinoxamine
  • paracarbinoxamine
  • paracarbinoxamine
  • paracarinoxamine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02656888Phase 3Jul 1, 2017EMS S/A
NCT02981147Phase 4May 1, 2017PharmEvo Pvt Ltd
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
EMS S/AFor profit1112017
PharmEvo Pvt LtdFor profit1112017
2 organizations
Page 1 / 1

Marketing (16)

OrganizationOrg typeRelationshipDate
AYTU BioScienceFor profitMKTGMar 28, 2013
AYTU BioScienceFor profitNDA2Mar 28, 2013
Apax PartnersFor profitMKTGFeb 26, 2008
Cypress PharmaceuticalFor profitMKTGMay 4, 2010
Endo PharmaceuticalsFor profitMKTGFeb 26, 2008
Genus Oncology, LLCFor profitMKTGMar 19, 2003
Invagen PharmsFor profitMKTGApr 15, 2010
Johnson and JohnsonFor profitNDA2Dec 27, 1974
Leading Pharma LlcFor profitMKTGDec 19, 2024
McNeilFor profitNDADec 27, 1974
MikartFor profitMKTGMar 19, 2003
Mission PharmacalFor profitMKTGMay 27, 2011
Mission PharmacalFor profitSYNMay 27, 2011
Strides Pharma ScienceFor profitMKTGMay 30, 2008
Tris Pharma, Inc.For profitNDA2Mar 28, 2013
VintageFor profitMKTGFeb 26, 2008